Charles River's $300 Million Question: The Volume Came Back, the Price Didn't
CRL delivers its best organic growth in three years and, for the first time in this cycle, quantifies 2027 — into a stock that had already given back 13% from its late-October high.
CRL · Earnings Call · 2026-11-04
A P&L story, finally
For six quarters Charles River has told a demand story it couldn't yet bank: proposals up, cancellations down, book-to-bill creeping toward — and then through — one. This quarter the demand finally landed in the income statement. “The solid DSA performance was supported by a net book-to-bill of 1.09x in the third quarter, which marks the fourth consecutive quarter that the net book-to-bill has been above 1x, averaging approximately 1.1x over this period.” — Birgit Girshick, Chief Executive Officer · 2026-11-04 Net bookings rose 32% to $652M, DSA backlog reached $2.03B, and that converted into 4.7% organic revenue growth — the strongest in three years — with non-GAAP operating margin at 23% (+330bp year over year) and earnings per share of $3.09, up 27%. DSA grew 5.9% organically to $596M, manufacturing 7.4% to $179M, while RMS slipped 0.6% to $208M. Guidance went up: organic growth to at least 1.5%, EPS to $11.35–$11.55. The optical trap is that reported revenue is still shrinking. Total revenue of $1.0B in the last filed quarter was down 3% year over year and sits about 5% below the 2023Q3 peak, and management guides full-year reported revenue down 1.5%–2% against organic growth above 1.5%. The same distortion runs through margins: the latest GAAP operating margin was 11.9%, nothing like the 23% adjusted number on the call. Even the company's own keyword set reflects the pivot — Create the Future transformation program and return to growth now crowd out the divestiture vocabulary that dominated 2025. Then there is the tape. CRL is up 43.9% over the last 90 days in one uninterrupted stretch, and it peaked at 376.10 on October 29 — yet by the November 4 call it sat 13.2% below that high and still 28.8% under the 2021 peak of 458.30. A name that roughly doubled off its low in about 32 weeks, de-rated sharply into the print, then got a raise.The lever nobody has pulled yet
Pricing is the hinge. For four quarters the language was passive — pricing would arrive when capacity tightened. In August: “pricing has not materially improved yet... any pricing uptick we might see in the upcoming quarters would flow through then in 2027, not before.” — Birgit Girshick, Chief Executive Officer · 2026-08-05 Now it is active: “we are beginning to modestly reduce the level of discounting in recent proposals” — Birgit Girshick, Chief Executive Officer · 2026-11-04. The conclusion on timing is identical — no benefit until at least the second half of 2027 — but the posture has flipped from waiting to testing. Pricing power has been a hoped-for theme since it first spiked in the keyword record as "return to pricing power" back in 2024; it is still a promise rather than a number, and management is admirably blunt that even success means only covering annual cost inflation.NHPs: the excuse became the moat
The highest-momentum phrase in CRL's own keyword extraction this quarter is human primate — non-human primate supply is the franchise's organizing fact. “about roughly 80% of our estimated usage is covered by our own supply from our own farms” — Birgit Girshick, Chief Executive Officer · 2026-11-04, a point Birgit Girshick frames as a competitive advantage that lets the company commit to study timing when rivals cannot. Cambodia NHP sourcing is the explicit driver of DSA's 26.8% margin and of the ~150bp sequential margin step guided for the fourth quarter, reinforced by the top-10 biopharma client that just named Charles River a primary strategic partner for safety assessment, with work transitioning over 12–18 months. The tell is what vanished. "Timing of NHP shipments" was a recurring crutch in this company's keyword history for the better part of three years, and it now registers as a decliner. Same animals, different sentence: from a quarterly volatility excuse to a structural cost advantage, captured in Safety Assessment study economics rather than logistics. Tightening supply in China is optionality management is explicitly choosing not to monetize yet.AI: the bear case finally gets an answer
Every CRO call gets the AI question. This one produced the cleanest rebuttal to the "AI compresses preclinical volumes" thesis that anyone on the beat has offered:That is a testable, falsifiable claim about program counts, and it is why AI platform now ranks among the company's top five extracted themes. Girshick's caveat is refreshingly un-promotional: “in two years, it's going to be hard to tell who's AI native and who uses AI and who doesn't use AI.” — Birgit Girshick, Chief Executive Officer · 2026-11-04 The market-wide tape already agrees on direction — IND enabling studies is one of the strongest 360-day advancers in the global theme tape, up roughly 136% across a basket of small biotechs, and still positive over 30 days. Preclinical demand is being priced; CRL's book-to-bill says it is arriving. Worth noting the candor around Virtual control groups, now moving from concept into a GLP-compliant study for Ipsen: “I wouldn't look at it as a huge revenue upside. I would say it's probably right alongside the being paid for regular control group.” — Birgit Girshick, Chief Executive Officer · 2026-11-04 A scientific milestone management chose to headline while admitting it is revenue-neutral is a signal about which audiences they are now optimizing for.In terms of more programs or less programs, qualitatively, what we are seeing is that often companies with AI platforms that they want to validate, they come in with more programs than generally a biotech company that is a non-AI company... They just need to have more volume going through that validation space.
What went quiet
Ten weeks ago the answer on next year was a flat refusal:Now: “In 2027, we expect operating margin improvement will be higher than the 75 basis point average through 2030... revenue growth increasing to the targeted 5%-7% range starting in 2028.” — Glenn Coleman, Executive Vice President and Chief Financial Officer · 2026-11-04 That is a genuine escalation of commitment, and it explains why long range and financial target sit in the top three of this quarter's keyword stack — Investor Day language migrating into guidance. Also quiet: the pre-IND versus post-IND mix debate that ran all year, and the tax-legislation overhang (the quarterly tax rate fell 550bp to 22.8%). What has not resolved is RMS: down 0.6% organically, margin off 60bp, with academic and government clients now nearly 40% of that segment and small-model pricing unable to offset services weakness — the one place government contract funding anxiety still bites. The balance sheet supports the story: leverage at 2.3x, effective net cash of -$2.4B, interest coverage of 4.0x, and free cash flow guided to $400–420M. But at 37.6x free cash flow less stock comp, after a 44% quarter, the next twelve months must deliver volume, then price, then RMS — roughly in that order. The 13% drawdown into the print suggests the market already banked the good quarter; the second half of 2027 is where the pricing promise either validates the multiple or doesn't.I think we're going to stay away from comments on 2027. That's a little bit early. There are too many variables in play that we still need to work through.